Fibrin Inhibitors
1 drugsAbout Fibrin
Fibrin is a protein essential for blood clot formation, polymerizing into a mesh-like network that stabilizes platelet plugs and stops bleeding. It is formed from fibrinogen through the action of thrombin.
While crucial for hemostasis, excessive fibrin formation contributes to thrombotic diseases, making it a therapeutic target. Currently, there is no genetic evidence directly linking fibrin to specific diseases.
Fibrin is targeted by one FDA-approved drug, TNKASE, a biologic. Roche is the only company with an approved fibrin-targeting drug.
Top Fibrin Drugs
Roche is the only company with an approved drug targeting fibrin.
Low competition suggests high barriers to entry or limited perceived market opportunity.
Fibrin Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Fibrin, using enzyme modality.
The lack of modality diversity indicates a whitespace opportunity for small molecules or antibodies.
Fibrin Clinical Trials 75 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Fibrin. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 0 | 0 | 2 | - |
| Phase 2 | 23 | 13 | 3 | 7 | 81% |
| Phase 3 | 40 | 15 | 5 | 20 | 75% |
| Phase 4 | 10 | 3 | 1 | 6 | 75% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved Fibrin drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting Fibrin. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Fibrin Drug Approval Timeline (2000 - 2000)
The first and only drug, TNKASE, was approved in 2000.
The lack of recent approvals suggests market saturation or challenges in developing new fibrin-targeting therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 44 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Fibrin. A trial counts if an approved drug acting on Fibrin is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.